COMMUNIQUÉS West-GlobeNewswire

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
20/04/2026
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]
Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve
20/04/2026
Purpose-built for the neocloud era: a unified view of Axe Compute's NASDAQ equity and its Strategic Compute Reserve (SCR), the operational reserve that funds enterprise access to 435,000+ GPUs across 200+ global [...]
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
20/04/2026
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time, reductions in “Off [...]
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
20/04/2026
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
20/04/2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease
20/04/2026
Berlin, Germany, and Durham, N.C., USA, April 20, 2026 (GLOBE NEWSWIRE) -- Not intended for UK Media Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to [...]
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
20/04/2026
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
20/04/2026
Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging’s platform RALEIGH, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation’s [...]
Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs
20/04/2026
New brand reflects years of expertise and a deepened commitment to the rare disease community FRISCO, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex [...]
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
20/04/2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in [...]
Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
20/04/2026
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical [...]
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
20/04/2026
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent Type C meeting [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
20/04/2026
President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026. The order directs acceleration of research and lowered barriers to approvals of psychedelic [...]
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
20/04/2026
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off- [...]
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
20/04/2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in [...]
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
20/04/2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic [...]
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
20/04/2026
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
20/04/2026
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage [...]
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
20/04/2026
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its [...]

Pages